Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $50.0M equity sale to Meiji at an 80% premium, providing non-dilutive-to-cash funding but issuing 2,466,395 shares.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50.0M equity sale to Meiji at an 80% premium, providing non-dilutive-to-cash funding but issuing 2,466,395 shares
- Meiji’s ARCT-154 license covers an undisclosed therapeutic area, with Meiji funding development and commercialization
- Potential Japan pandemic-preparedness license remains non-binding, creating strategic upside without a committed transaction
- Failure to sign the definitive Japan license by May 31, 2027 triggers an approximately $11.1M refund obligation
- Meiji faces a 365-day transfer lockup and 9.9% ownership cap, limiting near-term selling and control accumulation risk
Item 3.02 · Unregistered Sales of Equity Securities
- Unregistered share issuance under Section 4(a)(2), indicating a private placement exempt from Securities Act registration
- Shares subject to resale restrictions until registration or another exemption applies
- Investors should review Item 1.01 for purchase price, share count, proceeds, and registration-rights terms
Item 7.01 · Regulation FD Disclosure
- Press release announces transactions with Meiji, signaling a potentially material strategic or commercial development
- Exhibit 99.1 contains the transaction terms investors need to assess financial and operational impact
Item EX-99.1 · Exhibit EX-99.1
- $50M Meiji equity investment at $20.27 per share, an 80% premium and 7.9% post-transaction ownership
- Proceeds earmarked to accelerate ARCT-2601 development for OTC deficiency and clinically validate LUNAR 2.0
- Expanded collaboration includes an exclusive ARCT-154 license for an undisclosed therapeutic area
- Japan pandemic-preparedness MOU creates potential future collaboration and licensing revenue, but remains nonbinding
- Transaction strengthens funding and strategic validation while creating dilution for existing shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.